GLP-1 Receptor Agonists as Neuroprotective Agents in Alzheimer’s Disease: Mechanisms and Therapeutic Potential
Although Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used as a treatment for type 2 diabetes, and appear to be promising candidates for neuroprotection in Alzheimer's disease (AD). There has been an increase in evidence that suggests that GLP-1 signalling, beyond the metabolic regulation, seems to i...